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Abstract
Background:  Artemisinin-based combination therapy (ACT) is being widely promoted as a
strategy to counteract the increase in Plasmodium falciparum antimalarial drug resistance.
Methods: A randomized, double-blind, placebo-controlled, clinical trial of the efficacy, effect on
gametocytes and safety of the addition of artesunate/placebo (4 mg/kg/day × 3 d) to amodiaquine
(10 mg/kg/day × 3 d) was conducted in Choco department, a low intensity transmission area in
northwest Colombia.
Results: From 2,137 screened subjects, 85 entered the study: 43 in the amodiaquine plus placebo
and 42 in the amodiaquine plus artesunate groups. Potentially eligible cases failed to qualify mostly
because they were not available for follow-up visits (73%). Based on a per protocol analysis, the
therapeutic response to both treatments was high: amodiaquine/placebo 35/36, 97.2% (95% CI
85.5–99.9), and amodiaquine/artesunate 32/32, 100% (89.1–100) after PCR genotyping. The
Kaplan-Meier survival estimates based on all eligible patients enrolled (amodiaquine/placebo: n =
42; amodiaquine/artesunate: n = 41) were similar in the two study groups (P = 0.3). The addition
of artesunate significantly decreased gametocyte carriage on Day 4 (OR = 0.1 95% CI 0.02–0.6),
Day 7 (OR = 0.2 95%CI 0.04–0.9), Day 14 (OR = 0.09 95% CI 0–0.8), and Day 21 (OR95%CI 0–
0.9). Most subjects in both groups (81% in amodiaquine/placebo and 75.6% in amodiaquine/
artesunate) reported at least one drug related adverse event. Symptoms were generally mild and
self-limiting and there was no serious adverse event. Two patients on amodiaquine/artesunate
voluntarily withdrew from study because they could not tolerate the medication.
Conclusion:  Both drug regimens were effective in this area of Colombia. The addition of
artesunate reduced gametocyte carriage and did not adversely affect tolerability. In this set of
patients, the rate of adverse events was higher than in other studies. Patients' follow-up is
problematic in areas with dispersed population and affects the conduct of clinical studies and
monitoring of treatment effects. The results are discussed in the light of concurrent increase
resistance to amodiaquine in other endemic areas in Colombia and the factors that may influence
a change in the national antimalarial drug policy.
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Background
Since mid 2006, Colombia is the only country in South
America that has not yet introduced artemisinin-based
combination therapy (ACT) into its national malaria drug
policy for uncomplicated Plasmodium falciparum malaria.
Colombia accounted for 13.2% (116,872) of the 886,102
malaria cases reported in the Americas in 2004; of these,
44,437 (10.2%) were due to P. falciparum [1]. The Colom-
bian Ministry of Social Protection (formerly the Ministry
of Health) currently recommends amodiaquine (AQ) at a
dose of 25 mg/Kg over 48 h plus a single dose of sulfadox-
ine/pyrimethamine (SP) and primaquine (PQ, as a game-
tocytocidal drug) for the treatment for uncomplicated
falciparum malaria [2]. Malaria treatment is provided
free-of-charge to all microscopically-confirmed cases.
Combination therapy for P. falciparum malaria is not new
in Colombia. It was first used in the early 1980's when the
combination of chloroquine (CQ) plus SP was recom-
mended for all areas where CQ resistance had not been
reported and AQ plus SP for areas with known CQ resist-
ance. The combination of AQ plus SP was adopted for the
entire country in 1999, after reports of widespread CQ
resistance. The most recent clinical studies show that P.
falciparum therapeutic failure to CQ ranges from 67% to
97% in Antioquia (in the north), and from 44% to 70%
in the Pacific Coast region [3,4].
The efficacy of the AQ plus SP combination therapy
assessed after 21 days of follow-up is high in parts of
Colombia: 2 therapeutic failures out of 90 cases in Antio-
quia (Uraba and Bajo Cauca regions) [4], no failure in 49
cases in Nariño (city of Tumaco in the south-west). In the
Amazon region of Colombia, the efficacy of this combina-
tion has not been assessed. However, a high level (87.5%)
of therapeutic failure to SP monotherapy has been
reported in one endemic area bordering Brazil, where
widespread SP resistance is known to occur [5]. Gathering
data on the efficacy of antimalarial drugs in other areas of
the Colombian Amazon is limited by the availability of
suitable sites to conduct clinical studies with extended fol-
low up.
ACTs are currently recommended for the treatment of
uncomplicated falciparum malaria [6]. Artemisinin deriv-
atives are potent, rapidly acting antimalarials, which can
reduce gametocyte carriage and patient infectivity; the sus-
tained use of artesunate mefloquine reduced falciparum
malaria transmission and progression of drug resistance
in western Thailand [7,8]. A meta-analysis of a multi-
country study showed that the addition of artesunate (AS)
increased the efficacy of monotherapies without adversely
affecting tolerability, but that absolute cure rates
depended on the background resistance to the compan-
ion drug [9]. Colombia was one of the participating coun-
tries, but slow recruitment prevented the results of this
Colombian study from being published at the same time.
Here the results of a randomized, double blind clinical
trial of the therapeutic efficacy, effects on gametocytes and
safety of the addition of AS to AQ are presented and the
implications for treatment policy decision in Colombia
discussed.
Methods
Study site
The study was conducted in the town of Quibdo, the cap-
ital of Choco department in the northwest of Colombia
(05°42'N 76°40'W). Malaria is reported throughout the
year with annual parasite incidence rates ranging from
4.02 per 1,000 inhabitants in 1994 to 157.8 per 1,000
inhabitants in 1998. In the year 2000, a total of 1,206
malaria cases were reported in Quibdo municipality of
which 757 (63%) were due to P. falciparum. Subjects were
recruited at the San Vicente Health post and Ismael
Roldan hospital. These two sites diagnose more than 70%
of all malaria cases in this town. Health personnel in other
health posts were asked to refer potentially eligible sub-
jects who were interested in the study. The study was car-
ried out over two periods due to restrictions with study
drug availability: from April 27th, 2000 to November 30th,
2001 and from November 11th, 2002 to February 27th,
2004.
Entry criteria
Subjects with a positive thick smear were included if they
fulfilled all the following inclusion criteria: 1) pure P. fal-
ciparum  infection, 2) parasitaemia >500 and <50,000
asexual parasites/μL (subsequently the lower limit was
modified to >250 asexual parasites/μL), 3) age between 1
and 65 years old, and 4) availability to return for follow-
up. Subjects were excluded if they have any of the follow-
ing: 1) were pregnant, 2) had a history of allergy to the
study drugs, 3) had taken complete treatment with an
antimalarial drug in the previous 72 hours or sulphas,
clindamycin or tetracycline in the previous week, 4) had a
medical history of untreated hypertension or chronic
heart, kidney or liver disease, and 5) presented any danger
signs of severe malaria. [10] All subjects or their parents
(in the case of children under 18 years of age) were
requested to give written consent before entering the
study. This study was approved by the Ethical Committees
of CIDEIM, in Colombia, and of the WHO.
Laboratory procedures
At enrollment, 10 mL (7 mL in children ≤12 years old) of
venous blood was drawn to confirm the diagnosis of fal-
ciparum malaria with Giemsa stained thick and thin
smears, stored blood on filter paper for further parasite
genotyping, and to do a complete haemogram (manual),
ALT (Chemroy Canada Inc.), total bilirubin (ChemroyMalaria Journal 2007, 6:25 http://www.malariajournal.com/content/6/1/25
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Canada Inc.), and creatinine (Sera-Pak, Bayer). The
smears and filter paper blood samples were also collected
from finger pricks on Days 1, 2, 3, 4, 7, 14, 21 and 28; bio-
chemistry was repeated on Days 7 and 28. The laboratory
analyses were done at the Hospital Ismael Roldan in
Quibdo. The smears were read by a laboratory technicians
experienced in malaria diagnosis. Parasitaemia was calcu-
lated based on the number of asexual forms seen in 200
leucocytes and then multiplied by 40.
To distinguish between a recrudescent and a new infection
during follow-up, parasites identified from Days 14 to 28
were compared to those causing the initial episode using
PCR amplification of msp1, msp2 and glurp P. falciparum
genes from blood samples on filter paper according to
Snounou and Beck [11].
Treatment allocation and administration
All study subjects received AQ (Camoquin®  Sanofi,
France) 30 mg/kg (10 mg/kg/day or a maximum of 1,800
mg total) for three days and were randomly allocated,
using individual precoded opaque sealed envelopes, to AS
4 mg/kg/day (maximum 300 mg/day) or placebo for three
days. The coded envelopes and AS/placebo tablets were
prepared by Creapharm (France) and provided by Sanofi
(France). AQ and AS/placebo were administered together
with water and biscuits. A study nurse gave, observed, and
recorded all treatments. Treatment was repeated if vomit-
ing occurred within 30 minutes of the administered dose.
Subjects who failed treatment or had persistent drug
induced vomiting received quinine 10 mg/kg/day, three
times a day for three days plus clindamycin at 5 mg/kg
four times a day over five days.
Assessment of treatment response and effect on 
gametocytes
Therapeutic response was classified as Early Treatment
Failure (ETF), defined by any one of the following: 1)
development of danger signs or severe malaria on Days 1,
2, or 3, in the presence of parasitaemia; 2) parasite density
on Day 2 higher than day 0 count; and 3) Parasite density
on Day 3 ≥25% of count on Day 0. Late Treatment Failure
(LTF), defined by any one of the following: 1) Develop-
ment of danger signs or severe malaria after Day 3 in the
presence of parasitaemia; 2) Unscheduled return of the
patient because of clinical deterioration in the presence of
parasitaemia; 3) Presence of parasitaemia on any sched-
uled follow-up day on or after day 7. Adequate Clinical
Response (ACR): did not meet criteria for early or late
treatment failure and clearance of parasitaemia after Day
3 through Day 28 [12],
To assess the effect of treatment on gametocytes, the
number of gametocytes per 1,000 leucocytes was deter-
mined in Giemsa stained thick smears together with para-
sitaemia at enrollment and every visit.
Assessment of adverse effects
A physician or a nurse recorded any clinical events occur-
ring in the study subjects during follow-up and asked sys-
tematically for the presence of anorexia, nausea vomiting,
abdominal pain, diarrhoea, headache, dizziness, and any
other symptoms. The laboratory evaluations at enroll-
ment and on Days 7 and 28 were used to identify anaemia
(defined as haemoglobin <12 g/dL), leucopaenia (WBC
count <5,000/mm3), neutropaenia (total neu-
trophils<2,000/mm3), severe neutropaenia (<1,000/
mm3), liver toxicity (ALT> 48 U/L and/or a total bilirubin
>1 mg/dL), and renal toxicity (creatinine >1 mg/dL).
The results of the clinical and laboratory assessments were
considered as adverse events if they were new or increased
in severity with respect to the baseline data according to
CTC criteria of severity [13].
Adverse events were classified as probably associated with
the study treatment if: the adverse event followed a chron-
ological pattern with the treatment, and/or had been pre-
viously described for the study treatment, and could not
be explained by other factors including the clinical condi-
tion of the subject, other diseases or medications.
Sample size calculation
The sample size of 360 subjects (180 per study group) was
calculated based on an estimated 90% efficacy for AQ,
98% for AQ plus AS, with a two-sided 5% alpha error,
80% statistical power, and 12% estimated loss of subjects
to follow-up.
Data management and statistical analysis
Data were double entered and validated using Epinfo 6.04
d (Center for Disease Control and Prevention, USA). Sta-
tistical analysis was done using Epinfo 6.04 d and Stata
8.0 (Stata Corporation, 2003). Survival analysis using the
Kaplan Meier method and Log Rank test was carried out
to compare the therapeutic responses in the two study
groups on all patients enrolled except protocol violations.
The therapeutic response at Day 28 of follow-up with its
corresponding 95% confidence intervals was calculated
on subjects who adhered to the protocol for each study
group ("per protocol analysis"). For adverse event analy-
ses only those events that were classified as probably drug
related are reported.
Contingency tables and the chi-squared test were used to
assess differences in the proportion of subjects with game-
tocytes at each follow-up day between treatment groups.
An additional analysis was conducted only in subjectsMalaria Journal 2007, 6:25 http://www.malariajournal.com/content/6/1/25
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who were gametocyte negative at enrolment. A P-value
<5% was considered as statistically significant.
Results
A total of 2,137 subjects were screened in the two study
periods, from whom 1,933 (90.4%) were not eligible to
enter the study (Figure 1). The majority, 1,176/1,933
(61%) of subjects who were not eligible did not fulfill one
entry criterion and 39% (n = 757) did not meet two or
more entry criteria. Study ineligibility in the 1176 subjects
who did not meet one entry criterion was due to (i) ina-
bility to return for the 28 days of follow up (n = 861,
73.2%), (ii) low parasitaemia (n = 210, 17.9%), (iii) dan-
ger signs of severe malaria (n = 15, 1.3%), (iv) pregnancy
(n = 13, 1.1%), (v) age out of range (n = 9, 0.8%), (vi)
chronic disease (n = 6, 0.5%), (vii) previous complete
treatment with an antimalarial drug (n = 2, 0.2), and (viii)
other reasons (n = 60, 5.1%). Of the 204 subjects who
were eligible to enter the study, 119 (58.3%) did not
accept to participate and 85 did.
Of the total 85 subjects who entered the study, 43 were
randomized to AQ plus placebo and 42 to AQ plus AS; of
these, 71 were on the study on Day 14 and 69 on Day 28
(Figure 1). Two patients (one per arm) were excluded
from the efficacy and gametocyte analyses because they
were wrongly diagnosed. The subjects in the two groups
were comparable in their sociodemographic, clinical and
laboratory baseline characteristics. However, there were
more subjects with gametocytes at enrolment in the AQ
plus AS group (Table 1).
Only two treatment failures were observed, one in each
group. Both therapeutic failures were classified as LTF as
they occurred on Day 14 (AQ plus placebo group) and
Day 28 (AQ plus AS group). PCR genotyping showed
identical msp1 and msp2 amplifications but differences in
the fragment length of glurp in the samples obtained from
Day 0 and Day of failure in the AQ plus AS therapeutic
failure and hence the case was reclassified as a reinfection.
By contrast, the samples from Day 0 and the Day of failure
Study profile Figure 1
Study profile.Malaria Journal 2007, 6:25 http://www.malariajournal.com/content/6/1/25
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in the AQ plus placebo therapeutic failure were identical
and the case was considered as a true recrudescence. The
PCR corrected therapeutic responses for patients evalua-
ble at the Day 28 final visit were 35/36 or 97.2% (95%CI
85.5 – 99.9) for AQ plus placebo, and 32/32 or 100%
(89.1 – 100) for AQ plus AS. Excluding the two protocol
violations, 42 (AQ plus placebo) and 41 (AQ plus AS)
were included in the Kaplan Meier analyses; five and ten
subjects were censored during follow-up, respectively. The
Kaplan-Meier survival estimates were similar in the two
study groups for both crude (P = 0.9) and PCR-corrected
(P = 0.3) results.
Just under half of the AQ plus placebo group who did not
have gametocytes at enrollment had patent gametocytes at
some point during the 28 days of follow up (13/28
46.4%), compared to six of 22 (27.3%) of the AQ plus AS
group (P = 0.03). Gametocyte carriage peaked on Day 4
(14/33, 42.4%) in the AQ plus placebo group and on Day
7 (3/26, 11.5%) in the AQ plus AS-treated group. No
gametocytes were observed in the AQ plus AS group on
Day 21 and after. The differences in gametocyte carriage
between groups was statistically significant on Day 4 (OR
= 0.1 95%CI 0.02–0.6), Day 7 (OR = 0.2 95%CI 0.04–
0.9), Day 14 (OR = 0.09 95%CI 0–0.8), and Day 21 (OR
95% CI 0–0.9) (Figure 2). When the analysis was con-
ducted in all subjects regardless of the presence of game-
tocytes at enrollment, there was a statistically significant
difference in gametocyte carriage on Days 7 and 14: OR =
0.28 95%CI 0.08–1.02 for both days.
Adverse events were frequently reported in both study
groups; 34/42 (81%) and 31/41 (75.6%) subjects had at
least one adverse event considered to be probably associ-
ated with the antimalarial treatment in the AQ plus pla-
cebo and AQ plus AS group, respectively. Most events
were mild and self limiting or required short term symp-
tomatic treatment. However, two subjects in the AQ plus
AS group voluntarily withdrew from the study on Day 2,
one because of epigastric pain and the other because of
dizziness. There were no serious adverse events. Labora-
tory adverse events were also common but similar in the
two arms (Table 2). They were leucopaenia, neutropaenia,
anaemia and an increase in creatinine and ALT. By Day
28, total white blood cell counts ranged from 2,400 to
11,000/mm3 and leucopaenia was still present in 15/36
(42%) and 10/36 (27.8%) subjects in the AQ plus pla-
cebo and AQ plus AS group, respectively. The neutrophil
counts by Day 28 ranged from 417 to 8,140/mm3. Neu-
tropaenia (< 2,000/mm3) was observed in 10/36 (27.8%)
and 8/36 (22.2%) subjects in the placebo and AS groups,
respectively. Of these, six subjects (2 AQ and four in the
AQ plus AS groups) had total neutrophil counts <1,000/
mm3 but without apparent clinical ill effects. The subject
Table 1: Characteristics of study subjects at enrollment
Characteristic Amodiaquine/Placebo Artesunate/Amodiaquine
N = 37 (%) N = 34 (%)
Age (years old) Median 19 18.5
Range 5 to 62 3 to 58
Gender Male 24 (64.8) 27 (79.4)
Female 13 (35.2) 7 (20.6)
Weight (kg) Median 55 57
Range 19 to 99 12.5 to 80
Temperature (°C) Median 36.6 36.6
Range 35.9 to 39.0 36 to 40.2
Parasitaemia (asexual forms/μL) Geometric mean 3420 4416
Range 400 to 34,594 480 to 34,594
Presence of gametocytes Yes 4 (10.8) 8 (23.5)
No 33 (89.2) 26 (76.5)
Haemoglobin (g/dL) Median 11,6 12
Range 8.3 to 15.3 8.0 to 16.3
WBC/mm3 Median 5900 5200
Range 2200 to 12800 2000 to 15800
Neutrophils/mm3 Median 3264 2900
Range 1056 to 7134 1210 to 10428
Total bilirubin (mg/dL) Median 1 1.3
Range 0.2 to 5.3 0.1 to 5.2
ALT (U/L) Median 24 24.2
Range 2 to 98 5 to 107
Creatinine (mg/dL) Median 0.9 1
Range 0.4 to 1.9 0.4 to 1.4Malaria Journal 2007, 6:25 http://www.malariajournal.com/content/6/1/25
Page 6 of 9
(page number not for citation purposes)
with a neutrophil count of 417/mm3 was already neutro-
penic at baseline (1,056/mm3). There was a mild increase
in reticulocytes from Day 0 to Day 28 in both study
groups: from median (range) 0.6% (0.0–1.5) to 0.7%
(0.0–1.6) and from 0.5% (0.1–2.4) to 0.6% (0.0–1.4) in
the placebo and AS-treated groups, respectively. The mean
change in haemoglobin between Day 0 and Day 28 was
0.5 g/dL (range: -4.4, 3.7) for the AQ plus placebo group
and 0.1 g/dL (range: -3.4, 3.3) for the AQ plus AS group.
At Day 28, creatinine ranged from 0.4 to 2.0 mg/dL and
ALT from 2.0 to 105 U/L. Increased values of ALT (>48 U/
L) were observed in 3/72 (4.1%) subjects (one in AQ plus
placebo and two in AQ plus AS groups). A shift from nor-
mal laboratory results at baseline to abnormal at Day 28
was seen in 13/43 (34.9%) of subjects with respect to total
leucocyte counts (5,000/mm3), 15/64 (23.4%) for total
neutrophil counts (2,000/mm3), 10/38 (26.3%) for hae-
moglobin (12 g/dL), 4/33 (12.1%) for total bilirubin (1
mg/dL), 3/69 (4.3%) for creatinine (1.4 mg/dL) and 1/65
(1.5%) for ALT (48 U/L). All patients were clinically well.
Discussion
Artemisinin-based combination therapy (ACT) is being
widely promoted as a strategy to counteract increasing
resistance of P. falciparum to antimalarial drugs. the para-
sitological and clinical efficacy, effects on gametocytes
and safety of the addition of AS to AQ in an area of high
CQ-resistant P. falciparum malaria in Colombia, one of
the countries that has not yet officially adopted ACTs, was
evaluated.
In this study, there was a high therapeutic response to 30
mg/kg of AQ monotherapy (97.2%, 95% CI 85.8–99.9)
after 28 days. Similarly, the addition of AS showed a high
therapeutic efficacy (100%, 95%CI 89.1–100) with only
one recurrent parasitaemia on Day 28 that was reclassified
as a reinfection based on PCR genotyping. While the 95%
confidence intervals of both treatments overlap and the
small sample size is insufficient to demonstrate statistical
differences in efficacy between treatments, our results sug-
gest that AQ plus AS could be a suitable antimalarial ther-
apy in this area of Colombia. However, the results from
Quibdo may not be generalized to other endemic areas in
Colombia where high levels of therapeutic failure of 25
mg/kg AQ monotherapy have been reported. In recent
studies in three municipalities in the Southern pacific
coast (Tumaco, Guapi, and Buenaventura), AQ treatment
failures ranged from 33% to 50%, the majority being late
treatment failures [14]. The underlying levels of parasite
resistance are an important determinant of the policy
making process. Although the addition of AS increases the
efficacy of AQ alone in areas of Africa where parasitologi-
cal failures to AQ monotherapy varied from 21.1% to
59%, the therapeutic efficacy of the combination in these
areas is still low (from 85.1% to 68.4%) when compared
to alternatives such as other combinations with AS and
artemether/lumefantrine [9,15].
The effect of AS on gametocyte carriage, consistently seen
in other studies, was confirmed here (Figure 2) [9]. This is
a desirable characteristic of an antimalarial treatment
because this potentially reduces transmission and the
spread of resistant parasites [8]. For the same reason, the
Colombian Ministry of Health guidelines recommend a
single dose of PQ but its effectiveness in reducing gameto-
cyte carriage has not been evaluated. PQ may be associ-
ated to the risk of acute intravascular haemolysis when
give to G6PD deficient patients [16] One study found
12% prevalence in malaria patients in one endemic area
of the pacific coast of Colombia [17]. AS might be a more
efficacious, safer and an easier strategy than the addition
of PQ to antimalarial regimens for reducing gametocyte
carriage among P. falciparum infected individuals [18,19].
One small trial has shown that AS reduced gametocy-
togenesis, whilst 14 days of primaquine enhanced game-
tocyte clearance [20]. However, no field trial has been
conducted to evaluate the relative benefits of an ACT reg-
imen over one containing PQ in reducing malaria inci-
dence.
Adverse events were frequent in both study groups but dif-
ferences between placebo and AS were not detected (Table
2). A meta-analysis has shown that the addition of AS to
other antimalarials do not significantly increase the fre-
quency of adverse events. [9] Leucopaenia and neutropae-
nia have been previously described with AQ use and
Proportion of gametocyte carriers during follow up in each  study group Figure 2
Proportion of gametocyte carriers during follow up 
in each study group. Differences were statistically signifi-
cant on Days 4 (P = 0.003), 7 (P = 0.01), 14 (P = 0.01), and 21 
(P = 0.01).Malaria Journal 2007, 6:25 http://www.malariajournal.com/content/6/1/25
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related to the toxic effect of its quinoneimine metabolite
[21]. Although most of the study subjects did recover, the
overall frequencies of leucopaenia (25/72, 34.7%), neu-
tropaenia (18/72, 25%) and severe neutropaenia (6/72,
8.3%) at Day 28 were higher than those reported by Schel-
lenberg et al. (leucopaenia 3.7% and neutropenia 2.5% in
AQ-treated Tanzanian children) and by Adjuik et al.
("unremarkable changes in WBC" but similar figures for
severe neutropenia, namely, 6% in AQ or AQ plus AS-
treated African children) [9,22]. The definition of leuco-
paenia in the present study (WBC <5,000/mm3) was the
same as that used by Schellenberg et al, but neutropaenia
was defined differently: neutrophils <2,000/mm3 versus
<1,500/mm3 [22]. This study also showed a higher pro-
portion of patients with raised ALT >48 U/L than Schel-
lenberg et al: 9.7 vs. 3% [22]. The higher frequencies of
laboratory-observed adverse events could be explained by
co-morbidities or pharmacogenetic differences in the
study groups. Although there were no apparent clinical
consequences of the haematological and biochemical
changes in AQ-treated subjects, the findings of the present
study are a reminder that these AQ-related toxicities occur
after only one treatment. The consequences of its repeat
use, especially in areas of intense transmission, will need
to be monitored once AQ plus AS are deployed. Strategies
for implementing an antimalarial pharmacovigilance pro-
gramme in Africa have been proposed [23]. Colombia has
a national pharmacovigilance programme, but this needs
to be developed further, especially in malaria-endemic
areas.
Besides AS plus AQ, the current WHO malaria treatment
guidelines recommend three different ACTs: artemether-
lumefantrine (six dose regimen), AS plus mefloquine and
AS plus sulphadoxine/pyrimethamine (SP), that are being
used in South America [6]. This experience could help the
Colombian Ministry of Social Protection to decide which
ACTs represent the best options for the country in terms
of safety, cost, acceptability, use in pregnancy, treatment
of mixed infections (P. falciparum and Plasmodium vivax),
and logistics. Like Peru, Colombia may decide to have two
different first-line regimens according to geographical
areas, namely, one for the SP sensitive Pacific coast and
another for the SP resistant Amazon region, or it could opt
for an ACT that would have country-wide efficacy. On the
one hand, the advantage of having two first line regimens
would be to limit the use of second- and third-line drugs,
like quinine combined with an antibiotic or with meflo-
quine (usually more expensive and with less tolerability)
to areas of multidrug resistance. On the other hand, one
potential disadvantage would be the need to identify the
origin of infection before prescribing treatment, particu-
larly in the major cities, where people from both the Ama-
zon and Pacific Coast are seen and in areas of inter-
regional migration.
Before implementing ACTs in Colombia, it is important
to highlight that, in spite of reports of therapeutic failures
to both AQ and SP as monotherapies, the efficacy of their
combined use (AQ plus SP, the current national antima-
larial drug policy) has been shown to be 97% or more in
the Pacific Coast and northern Colombia [24]. However,
the AQ plus SP efficacy studies followed up subjects up to
21 days which means that later treatment failures were not
detected. Longer follow up is desirable when assessing the
therapeutic efficacy of drugs with long half lives such as
AQ and SP, but they are not feasible in the endemic areas
in Colombia where the studies have been conducted.
Table 2: Clinical and laboratory adverse events probably associated with the antimalarial treatment by study group that were 
recorded at least once during follow up.
Adverse event1 Amodiaquine/Placebo Amodiaquine/Artesunate
N = 34 (%) N = 31 (%)
Leucopaenia 18 (52,9) 13 (41,9)
Neutropaenia 16 (47,1) 15 (48,4)
Anaemia 10 (29,4) 7 (22,6)
ALT> 48 U/L 6 (17,6) 4 (12,9)
Vomit 5 (14,7) 2 (6,5)
Dizziness 5 (14,7) 6 (19,4)
Abdominal pain 5 (14,7) 4 (12,9)
Bilirubin >1 mg/dL 5 (14,7) 6 (19,4)
Itching 4 (11,8) 4 (12,9)
Headache 3 (8,8) 0 (0)
Diarrhoea 2 (5,9) 2 (6,5)
Anorexia 2 (5,9) 1 (3,2)
Nausea 1 (2,9) 3 (9,7)
1Definitions: leucopaenia (WBC<5,000/mm3), neutropaenia (total neutrophils<2,000/mm3), anaemia (haemoglobin <12 g/dL). ALT: Alanine Amino 
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Indeed, the main limitation for achieving the required
sample size in the present study was the unavailability of
subjects to come back for follow up for 28 days. Although
the efficacy of AQ plus SP could be over estimated, in
comparison to the currently available ACTs, it is cheap
and can be used in all trimesters of pregnancy. The poten-
tial impact of ACT in controlling falciparum malaria is
influencing the thinking of the national malaria control
programme towards introducing ACTs. However, to take
full advantage of ACTs, the malaria control programme
should be able to guarantee the timely provision of qual-
ity formulations, proper training for prescribers, appropri-
ate storage of drugs in the hot and humid environments
in endemic areas, and design strategies to encourage
adherence (e.g. use of co-formulations or blisters). A dif-
ferent therapeutic scheme to treat malaria in pregnancy,
especially in the first trimester, in areas where an ACT is
deployed may be required because more data are needed
on the efficacy and safety of ACTs in this population[19].
A malaria control programme that provides early diagno-
sis and access to an efficacious antimalarial treatment is
essential to decrease malaria transmission in endemic
regions.
Conclusion
AQ plus AS was efficacious in subjects with uncompli-
cated P. falciparum malaria in one endemic area in Colom-
bia and reduced gametocyte carriage compared to AQ
alone. However, the relative high frequency of adverse
events attributable to AQ found and the reports of AQ
resistance in other endemic areas of Colombia suggest
that other ACT options should be considered for Colom-
bia.
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